Linvoseltamab data in AL amyloidosis could have ‘tremendous implications’

CHICAGO — The bispecific antibody linvoseltamab exhibited rapid clinical activity among patients with relapsed or refractory systemic light chain amyloidosis, according to phase 1/phase 2 trial results presented at ASCO Annual Meeting.All 20 treated patients achieved objective response and 18 achieved hematologic complete response.

Raccontata dahealio.com